The influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement.

ABSTRACT:

Background

Elevated levels of lipoprotein(a) (Lp[a]) have been recognized as substantial risk factors for cardiovascular disease and aortic stenosis (AS). However, the specific role of Lp(a) in promoting aortic valve calcification (AVC) and influencing mortality in elderly, multimorbid patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear and warrants further investigation.

Methods

A retrospective analysis was conducted on all consecutive patients who underwent TAVR between August 2019 and June 2020 at our clinic. Patients with missing data or prior aortic valve replacement were excluded. The study cohort was stratified based on an Lp(a) threshold of 60 mg/dl according to guidelines for lipoprotein apheresis in UK and Germany.^1,2 RESULT

SUBMITTER: Bormann J 

PROVIDER: S-EPMC11913987 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature